Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aclaris Therapeutics, Inc.ACRS · Entity 5041 | Director | June 01, 2024 | June 04, 2024 |
| Amneal Pharmaceuticals, Inc.AMRX · Entity 820 | CFO | August 21, 2018 | August 23, 2018 |
| Keenova Therapeutics plcNONE · Entity 28960 | EVP & CFO | July 31, 2025 | August 04, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aclaris Therapeutics, Inc.
Report date June 01, 2024 · Filed June 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,732 |
Reported balance
After 2024-06-01 transaction · row 1
1 source rowRow 1 · 2024-06-01 · Exercise / conversion · Acquired 4,660 · Balance 28,732 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-06-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-01 · Exercise / conversion · Disposed 4,660 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2: The shares underlying these restricted stock units vested on June 1, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2: The shares underlying these restricted stock units vested on June 1, 2024.
Amneal Pharmaceuticals, Inc.
Report date August 21, 2018 · Filed August 23, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 82,986 |
Reported balance
After 2018-08-21 transaction · row 1
1 source rowRow 1 · 2018-08-21 · Sale · Disposed 11,698 · Balance 82,986 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.55 to $23.78. The reporting person undertakes to provide Amneal Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.55 to $23.78. The reporting person undertakes to provide Amneal Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Keenova Therapeutics plc
Report date July 31, 2025 · Filed August 04, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 54,714 |
Reported balance
After 2025-07-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-07-31 · Grant · Acquired 41,035 · Balance 54,714 F1: On July 31, 2025, pursuant to the Transaction Agreement, dated as of March 13, 2025 (as amended, the "Transaction Agreement"), by and among Mallinckrodt plc (the "Issuer"), Endo, Inc. ("Endo") and Salvare Merger Sub LLC, the Issuer's wholly owned subsidiary ("Merger Sub"), the Merger Sub merged with and into Endo (the "Business Combination"), with Endo surviving the Business Combination as a wholly owned subsidiary of the Issuer. F2: Upon consummation of the Business Combination, each performance unit ("PSU") held by the reporting person automatically converted into a restricted unit ("RSU"). Each RSU will fully vest on December 25, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 31, 2025, pursuant to the Transaction Agreement, dated as of March 13, 2025 (as amended, the "Transaction Agreement"), by and among Mallinckrodt plc (the "Issuer"), Endo, Inc. ("Endo") and Salvare Merger Sub LLC, the Issuer's wholly owned subsidiary ("Merger Sub"), the Merger Sub merged with and into Endo (the "Business Combination"), with Endo surviving the Business Combination as a wholly owned subsidiary of the Issuer.
F2: Upon consummation of the Business Combination, each performance unit ("PSU") held by the reporting person automatically converted into a restricted unit ("RSU"). Each RSU will fully vest on December 25, 2026.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Impax Laboratories, LLC
Report date May 04, 2018 · Filed May 08, 2018
Section 16 reporting ended · disclosed 2018-05-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 1
1 source rowRow 1 · 2018-05-04 · Disposition to issuer · Disposed 53,423 · Balance 0 F1: Common Stock disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017 (the "BCA"), by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017, according to which each share of Common Stock held by the reporting person was converted into the right to receive one share of Class A common stock of Holdco ("Class A Common Stock"). |
| Restricted Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 2
1 source rowRow 2 · 2018-05-04 · Disposition to issuer · Disposed 20,566 · Balance 0 F2: Shares of restricted common stock disposed of pursuant to the terms of the BCA, according to which each share of restricted stock held by the reporting person fully vested and was exchanged for one share of Class A Common Stock. Amount represents net amount of shares exchanged after required tax withholding with respect to such vesting. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.35 · Expires 2027-03-02 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-05-04 · Disposition to issuer · Disposed 56,232 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.27 · Expires 2026-02-26 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-05-04 · Disposition to issuer · Disposed 63,095 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.70 · Expires 2025-02-26 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-05-04 · Disposition to issuer · Disposed 47,500 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.24 · Expires 2024-05-14 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-05-04 · Disposition to issuer · Disposed 55,000 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.99 · Expires 2023-05-15 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-05-04 · Disposition to issuer · Disposed 52,000 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Common Stock disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017 (the "BCA"), by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017, according to which each share of Common Stock held by the reporting person was converted into the right to receive one share of Class A common stock of Holdco ("Class A Common Stock").
F2: Shares of restricted common stock disposed of pursuant to the terms of the BCA, according to which each share of restricted stock held by the reporting person fully vested and was exchanged for one share of Class A Common Stock. Amount represents net amount of shares exchanged after required tax withholding with respect to such vesting.
F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option.
Societal CDMO, Inc.
Report date April 08, 2024 · Filed April 08, 2024
Section 16 reporting ended · disclosed 2024-04-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-04-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-04-08 · Other · Disposed 217,429 · Balance 73,620 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 28, 2024, by and among the Issuer, CoreRx, Inc., a Florida corporation ("Parent") and Cane Merger Sub, Inc., a Pennsylvania corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of April 8, 2024 (the "Effective Time") with the Issuer surviving the merger. At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $1.10 per Share in cash (the "Offer Amount"), subject to any applicable withholding taxes and without interest. Row 2 · 2024-04-08 · Disposition to issuer · Disposed 73,620 · Balance 0 F2: Represents restricted stock units granted under an Issuer equity plan ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one Share upon vesting of the RSU. Pursuant to the terms of the Merger Agreement, each outstanding RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each RSU then outstanding was cancelled and converted into a cash payment equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Offer Amount, without interest and subject to any withholding of taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.80 | Direct | 0 |
Reported balance
After 2024-04-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-04-08 · Disposition to issuer · Disposed 118,182 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") vested in full. At the Effective Time, each Issuer Stock Option with an exercise price that is less than the Offer Amount was cancelled and converted into the right to receive a cash payment equal to the product of (A) the excess, if any, of the Offer Amount over the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.74 | Direct | 0 |
Reported balance
After 2024-04-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-04-08 · Disposition to issuer · Disposed 27,229 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") vested in full. At the Effective Time, each Issuer Stock Option with an exercise price that is less than the Offer Amount was cancelled and converted into the right to receive a cash payment equal to the product of (A) the excess, if any, of the Offer Amount over the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 28, 2024, by and among the Issuer, CoreRx, Inc., a Florida corporation ("Parent") and Cane Merger Sub, Inc., a Pennsylvania corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of April 8, 2024 (the "Effective Time") with the Issuer surviving the merger. At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $1.10 per Share in cash (the "Offer Amount"), subject to any applicable withholding taxes and without interest.
F2: Represents restricted stock units granted under an Issuer equity plan ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one Share upon vesting of the RSU. Pursuant to the terms of the Merger Agreement, each outstanding RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each RSU then outstanding was cancelled and converted into a cash payment equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Offer Amount, without interest and subject to any withholding of taxes.
F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") vested in full. At the Effective Time, each Issuer Stock Option with an exercise price that is less than the Offer Amount was cancelled and converted into the right to receive a cash payment equal to the product of (A) the excess, if any, of the Offer Amount over the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 09, 2019 Filed May 10, 2019 16:25 UTC | Societal CDMO, Inc. REPH · Entity 92137 | GrantCommon Stock | 7,955 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000244 · edgar.xml · nonDerivative · entry 1 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,987 F1 · shares: All shares of common stock are represented by unvested restricted stock units that will vest on May 9, 2020. Vested shares will be delivered to the reporting person within 30 days following the vesting date. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 18:16 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantEmployee Share Options (Right to Buy) · Derivative | 57,569 | $0.00 Strike: $22.26 | $0.00 |
DisclosureSEC source: 0000950138-19-000233 · edgar.xml · derivative · entry 2 Reasons Bryan M. · CIK 0001553489 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,569 Underlying: Ordinary Shares · 57,569 shares Expires 2029-04-01 F2 · derivative.exercise_date: The options vest in four equal annual installments beginning April 1, 2020. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 18:16 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 12,579 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000233 · edgar.xml · nonDerivative · entry 1 Reasons Bryan M. · CIK 0001553489 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,579 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning April 1, 2020. Read SEC document |
| August 21, 2018 Filed Aug 23, 2018 20:50 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 11,698 | $23.65 | $276,657.70 |
DisclosureSEC source: 0000899243-18-023153 · doc4.xml · nonDerivative · entry 1 Reasons Bryan M. · CIK 0001553489 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,986 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.55 to $23.78. The reporting person undertakes to provide Amneal Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 12, 2018 Filed May 14, 2018 16:48 UTC | Societal CDMO, Inc. REPH · Entity 92137 | Exercise / conversionRestricted Stock Units · Derivative | 8,849 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-18-000203 · edgar.xml · derivative · entry 2 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,849 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On May 12, 2017, the reporting person was granted 8,849 restricted stock units, vesting on the first anniversary of the grant date. F2 · derivative.expiration_date: On May 12, 2017, the reporting person was granted 8,849 restricted stock units, vesting on the first anniversary of the grant date. Read SEC document |
| May 12, 2018 Filed May 14, 2018 16:48 UTC | Societal CDMO, Inc. REPH · Entity 92137 | Exercise / conversionCommon Stock | 8,849 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-18-000203 · edgar.xml · nonDerivative · entry 1 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,032 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| May 07, 2018 Filed May 8, 2018 23:22 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 33,311 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-011942 · doc4.xml · derivative · entry 8 Reasons Bryan M. · CIK 0001553489 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,311 Underlying: Class A Common Stock · 33,311 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F6 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on May 07, 2019 and have no expiration date. F6 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on May 07, 2019 and have no expiration date. Read SEC document |
| May 07, 2018 Filed May 8, 2018 23:22 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 136,240 | $0.00 Strike: $15.01 | $0.00 |
DisclosureSEC source: 0000899243-18-011942 · doc4.xml · derivative · entry 7 Reasons Bryan M. · CIK 0001553489 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,240 Underlying: Class A Common Stock · 136,240 shares Expires 2028-05-07 F4 · derivative.exercise_date: The option vests in four equal annual installments beginning on May 07, 2019. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:08 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerStock Option (Right to Buy) · Derivative | 52,000 | Not disclosed Strike: $17.99 | Not disclosed |
DisclosureSEC source: 0001003642-18-000078 · wf-form4_152581008008892.xml · derivative · entry 7 Reasons Bryan M. · CIK 0001553489 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 52,000 shares Expires 2023-05-15 F3 · shares: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · price: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · derivative.exercise_date: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:08 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerStock Option (Right to Buy) · Derivative | 55,000 | Not disclosed Strike: $25.24 | Not disclosed |
DisclosureSEC source: 0001003642-18-000078 · wf-form4_152581008008892.xml · derivative · entry 6 Reasons Bryan M. · CIK 0001553489 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,000 shares Expires 2024-05-14 F3 · shares: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · price: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · derivative.exercise_date: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:08 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerStock Option (Right to Buy) · Derivative | 47,500 | Not disclosed Strike: $40.70 | Not disclosed |
DisclosureSEC source: 0001003642-18-000078 · wf-form4_152581008008892.xml · derivative · entry 5 Reasons Bryan M. · CIK 0001553489 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 47,500 shares Expires 2025-02-26 F3 · shares: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · price: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · derivative.exercise_date: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:08 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerStock Option (Right to Buy) · Derivative | 63,095 | Not disclosed Strike: $33.27 | Not disclosed |
DisclosureSEC source: 0001003642-18-000078 · wf-form4_152581008008892.xml · derivative · entry 4 Reasons Bryan M. · CIK 0001553489 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 63,095 shares Expires 2026-02-26 F3 · shares: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · price: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · derivative.exercise_date: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:08 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerStock Option (Right to Buy) · Derivative | 56,232 | Not disclosed Strike: $9.35 | Not disclosed |
DisclosureSEC source: 0001003642-18-000078 · wf-form4_152581008008892.xml · derivative · entry 3 Reasons Bryan M. · CIK 0001553489 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 56,232 shares Expires 2027-03-02 F3 · shares: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · price: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · derivative.exercise_date: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:08 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerRestricted Common Stock | 20,566 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001003642-18-000078 · wf-form4_152581008008892.xml · nonDerivative · entry 2 Reasons Bryan M. · CIK 0001553489 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · shares: Shares of restricted common stock disposed of pursuant to the terms of the BCA, according to which each share of restricted stock held by the reporting person fully vested and was exchanged for one share of Class A Common Stock. Amount represents net amount of shares exchanged after required tax withholding with respect to such vesting. F2 · price: Shares of restricted common stock disposed of pursuant to the terms of the BCA, according to which each share of restricted stock held by the reporting person fully vested and was exchanged for one share of Class A Common Stock. Amount represents net amount of shares exchanged after required tax withholding with respect to such vesting. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:08 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerCommon Stock | 53,423 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001003642-18-000078 · wf-form4_152581008008892.xml · nonDerivative · entry 1 Reasons Bryan M. · CIK 0001553489 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Common Stock disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017 (the "BCA"), by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017, according to which each share of Common Stock held by the reporting person was converted into the right to receive one share of Class A common stock of Holdco ("Class A Common Stock"). F1 · price: Common Stock disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017 (the "BCA"), by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017, according to which each share of Common Stock held by the reporting person was converted into the right to receive one share of Class A common stock of Holdco ("Class A Common Stock"). Read SEC document |
| May 04, 2018 Filed May 8, 2018 23:22 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 52,000 | Not disclosed Strike: $17.99 | Not disclosed |
DisclosureSEC source: 0000899243-18-011942 · doc4.xml · derivative · entry 6 Reasons Bryan M. · CIK 0001553489 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,000 Underlying: Class A Common Stock · 52,000 shares Expires 2023-05-15 F3 · price: Received pursuant to the BCA in exchange for an option to purchase an equal number of shares of Impax common stock. F2 · derivative.exercise_date: The option is vested and currently exercisable. Read SEC document |
| May 04, 2018 Filed May 8, 2018 23:22 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 55,000 | Not disclosed Strike: $25.24 | Not disclosed |
DisclosureSEC source: 0000899243-18-011942 · doc4.xml · derivative · entry 5 Reasons Bryan M. · CIK 0001553489 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Class A Common Stock · 55,000 shares Expires 2024-05-14 F3 · price: Received pursuant to the BCA in exchange for an option to purchase an equal number of shares of Impax common stock. F2 · derivative.exercise_date: The option is vested and currently exercisable. Read SEC document |
| May 04, 2018 Filed May 8, 2018 23:22 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 47,500 | Not disclosed Strike: $40.70 | Not disclosed |
DisclosureSEC source: 0000899243-18-011942 · doc4.xml · derivative · entry 4 Reasons Bryan M. · CIK 0001553489 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,500 Underlying: Class A Common Stock · 47,500 shares Expires 2025-02-26 F3 · price: Received pursuant to the BCA in exchange for an option to purchase an equal number of shares of Impax common stock. F2 · derivative.exercise_date: The option is vested and currently exercisable. Read SEC document |
| May 04, 2018 Filed May 8, 2018 23:22 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 63,095 | Not disclosed Strike: $33.27 | Not disclosed |
DisclosureSEC source: 0000899243-18-011942 · doc4.xml · derivative · entry 3 Reasons Bryan M. · CIK 0001553489 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,095 Underlying: Class A Common Stock · 63,095 shares Expires 2026-02-26 F3 · price: Received pursuant to the BCA in exchange for an option to purchase an equal number of shares of Impax common stock. F2 · derivative.exercise_date: The option is vested and currently exercisable. Read SEC document |
| May 04, 2018 Filed May 8, 2018 23:22 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 56,232 | Not disclosed Strike: $9.35 | Not disclosed |
DisclosureSEC source: 0000899243-18-011942 · doc4.xml · derivative · entry 2 Reasons Bryan M. · CIK 0001553489 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,232 Underlying: Class A Common Stock · 56,232 shares Expires 2027-03-02 F3 · price: Received pursuant to the BCA in exchange for an option to purchase an equal number of shares of Impax common stock. F2 · derivative.exercise_date: The option is vested and currently exercisable. Read SEC document |
| May 04, 2018 Filed May 8, 2018 23:22 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantClass A Common Stock | 94,684 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-011942 · doc4.xml · nonDerivative · entry 1 Reasons Bryan M. · CIK 0001553489 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,684 F1 · price: Received in exchange for 94,684 shares of Impax Laboratories, Inc. ("Impax") common stock pursuant to the Business Combination Agreement, dated as of October 17, 2017, among Impax, Amneal Pharmaceuticals LLC, Atlas Holdings, Inc. and K2 Merger Sub Corporation (as amended, the "BCA"). Read SEC document |
| May 04, 2018 Filed May 8, 2018 17:28 UTC | Societal CDMO, Inc. REPH · Entity 92137 | GrantStock Option (right to buy) · Derivative | 5,742 | $0.00 Strike: $11.32 | $0.00 |
DisclosureSEC source: 0001192482-18-000185 · edgar.xml · derivative · entry 2 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,742 Underlying: Common Stock · 5,742 shares Expires 2028-05-04 F2 · derivative.exercise_date: The stock option will vest on May 4, 2019. Read SEC document |
| May 04, 2018 Filed May 8, 2018 17:28 UTC | Societal CDMO, Inc. REPH · Entity 92137 | GrantCommon Stock | 6,183 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-18-000185 · edgar.xml · nonDerivative · entry 1 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,183 F1 · shares: All shares of common stock are represented by unvested restricted stock units that will vest on May 4, 2019. Vested shares will be delivered to the reporting person within 30 days following the vesting date. Read SEC document |
| May 04, 2018 Filed May 10, 2018 19:01 UTC Amendment | Societal CDMO, Inc. REPH · Entity 92137 | GrantStock Option (right to buy) · Derivative | 8,965 | $0.00 Strike: $11.32 | $0.00 |
DisclosureSEC source: 0001192482-18-000199 · edgar.xml · derivative · entry 1 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,965 Underlying: Common Stock · 8,965 shares Expires 2028-05-04 F1 · shares: This amended Form 4 is being filed to correct a typographical error in the number of stock options acquired on May 4, 2018 as reported on the Form 4 filed on May 8, 2018. F2 · derivative.exercise_date: The stock option will vest on May 4, 2019. Read SEC document |
| April 20, 2018 Filed Apr 23, 2018 18:29 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $17.73 | $0.00 |
DisclosureSEC source: 0001209191-18-025908 · doc4.xml · derivative · entry 1 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2028-04-19 F1 · derivative.exercise_date: This option will vest and become exercisable in 36 equal monthly installments through April 20, 2021, subject to the reporting person's continuous service as of such vesting dates. Read SEC document |
| March 02, 2018 Filed Mar 5, 2018 12:46 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Tax withholdingCommon Stock | 3,069 | $19.50 | $59,845.50 |
DisclosureSEC source: 0001003642-18-000046 · wf-form4_152027197326277.xml · nonDerivative · entry 1 Reasons Bryan M. · CIK 0001553489 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,684 F1 · shares: These shares of common stock were withheld by the issuer upon the vesting of a restricted stock award to satisfy Mr. Reasons' payroll tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 26, 2018 Filed Feb 27, 2018 12:19 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Tax withholdingCommon Stock | 6,141 | $20.95 | $128,653.95 |
DisclosureSEC source: 0001003642-18-000023 · wf-form4_151975193527224.xml · nonDerivative · entry 1 Reasons Bryan M. · CIK 0001553489 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,753 F1 · kind: These shares of common stock were withheld by the issuer upon the vesting of two restricted stock awards to satisfy Mr. Reasons' payroll tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 15, 2017 Filed May 16, 2017 14:54 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Tax withholdingCommon Stock | 454 | $16.80 | $7,627.20 |
DisclosureSEC source: 0001003642-17-000044 · wf-form4_149496086190888.xml · nonDerivative · entry 2 Reasons Bryan M. · CIK 0001553489 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,894 F1 · shares: These shares of common stock were withheld by the issuer upon the vesting of a restricted stock award to satisfy Mr. Reasons' payroll tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 14, 2017 Filed May 16, 2017 14:54 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Tax withholdingCommon Stock | 705 | $17.65 | $12,443.25 |
DisclosureSEC source: 0001003642-17-000044 · wf-form4_149496086190888.xml · nonDerivative · entry 1 Reasons Bryan M. · CIK 0001553489 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,348 F1 · shares: These shares of common stock were withheld by the issuer upon the vesting of a restricted stock award to satisfy Mr. Reasons' payroll tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 12, 2017 Filed May 16, 2017 16:30 UTC | Societal CDMO, Inc. REPH · Entity 92137 | GrantRestricted Stock Units · Derivative | 8,849 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-17-000944 · edgar.xml · derivative · entry 1 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,849 Underlying: Common Stock · 8,849 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F2 · derivative.exercise_date: The restricted stock units vest on May 12, 2018. Vested shares will be delivered to the reporting person within 30 days following the vesting date. F2 · derivative.expiration_date: The restricted stock units vest on May 12, 2018. Vested shares will be delivered to the reporting person within 30 days following the vesting date. Read SEC document |
| March 03, 2017 Filed Mar 6, 2017 16:59 UTC | Societal CDMO, Inc. REPH · Entity 92137 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $7.63 | $0.00 |
DisclosureSEC source: 0001123292-17-000562 · edgar.xml · derivative · entry 1 Reasons Bryan M. · CIK 0001553489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-03-03 F1 · derivative.exercise_date: The option vests in three equal installments on March 3, 2018, 2019, and 2020. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 15:08 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | GrantStock Option (Right to Buy) · Derivative | 56,232 | $0.00 Strike: $9.35 | $0.00 |
DisclosureSEC source: 0001003642-17-000019 · wf-form4_148883086849313.xml · derivative · entry 2 Reasons Bryan M. · CIK 0001553489 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,232 Underlying: Common Stock · 56,232 shares Expires 2027-03-02 F1 · derivative.exercise_date: The option vests in four equal installments beginning on March 2, 2018, which is the first anniversary of the grant date. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 15:08 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | GrantCommon Stock | 23,272 | $0.00 | $0.00 |
DisclosureSEC source: 0001003642-17-000019 · wf-form4_148883086849313.xml · nonDerivative · entry 1 Reasons Bryan M. · CIK 0001553489 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,053 Read SEC document |
| February 26, 2017 Filed Feb 27, 2017 20:23 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Tax withholdingCommon Stock | 5,715 | $14.05 | $80,295.75 |
DisclosureSEC source: 0001003642-17-000012 · wf-form4_148824498735141.xml · nonDerivative · entry 1 Reasons Bryan M. · CIK 0001553489 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,781 F1 · shares: These shares of common stock were withheld by the issuer upon the vesting of two restricted stock awards to satisfy Mr. Reasons' payroll tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| October 26, 2016 Filed Oct 27, 2016 12:05 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Tax withholdingCommon Stock | 1,209 | $21.35 | $25,812.15 |
DisclosureSEC source: 0001003642-16-000038 · wf-form4_147758430494937.xml · nonDerivative · entry 1 Reasons Bryan M. · CIK 0001553489 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,496 F1 · shares: These shares of common stock were withheld by the issuer upon the vesting of a restricted stock award to satisfy Mr. Reasons' payroll tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.